Nxera Licenses GPCR Program To NewCo, Secures Equity Stake And Future Royalties, Partners With Investor-Backed NewCo To Advance GPCR Asset Globally

Nxera Pharma Co., Ltd. has entered into a license agreement with a newly formed independent company (NewCo), established by a leading international life sciences investment firm, to advance its G protein-coupled receptor (GPCR)-targeted program.

Under the terms of the agreement, Nxera has received an equity stake in NewCo and will be eligible for milestone payments and sales-based royalties if the program is successfully developed and commercialised. Importantly, Nxera has retained certain future rights to develop and commercialise the asset in Japan and selected Asia-Pacific territories. Specific financial terms were not disclosed due to contractual confidentiality.

The partnership is designed to leverage NewCo’s development expertise and capital-raising capabilities, allowing the GPCR program to progress efficiently while maximising long-term value. Nxera also retains the option to participate in NewCo’s upcoming Series A financing round alongside major global investors.

The company stated that the financial impact of the agreement on its consolidated results for the fiscal year ending December 31, 2026, is currently under review, and further disclosures will be made if required.